The Impact of Emerging Infectious Diseases on Military Operations

Similar documents
TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

The Application of Contagious Disease Epidemiological Models to Known Population Structure and Movement

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

Award Number: W81XWH

Detection of Prostate Cancer Progression by Serum DNA Integrity

INTENSITY REDISTRIBUTION FOR MILTICONJUGATE ADAPTIVE OPTICS (Postprint)

Final Performance Report. Contract # FA C-0006: Hearing Protection for High-Noise Environments Period of Performance: Oct 01, 2007 Nov 30, 2009

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

Approved for public release; distribution unlimited

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

Fort Detrick, Maryland

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

Award Number: W81XWH

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AFRL-RH-WP-TR

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

TITLE: Treatment of Dengue Virus Infection with Repurposed Pharmaceuticals that Inhibit Autophagy

CONTRACTING ORGANIZATION: Veterans Medical Research Foundation San Diego, CA

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

Approved for public release; distribution unlimited

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

Anti-Viral Prophylaxis Target Product Profile Guidelines

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: West Virginia University Morgantown, West Virginia

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

TITLE: Determination of Optimum Vitamin D Nutrition in Young Women. Omaha, NE 68178

Promote Adjustment during Reintegration following Deployment

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

Pandemic Influenza: Appropriations for Public Health Preparedness and Response

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Exploring Early Detection Methods: Using the Intraductal Approach to Predict Breast Cancer

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland X Approved for public release; distribution unlimited

Spatial Transformations in Graph Comprehension

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

Report Documentation Page

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

Long-Term Health Effects of Embedded Depleted Uranium

Mid-Season Influenza Vaccine Effectiveness for the Influenza Season

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: MIPR 3GD3DN3081. TITLE: Outcomes of Telehealth Group Psychosocial Interventions for Breast Cancer Patients and Their Partners

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108

TITLE: Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD

La Jolla, CA Approved for Public Release; Distribution Unlimited

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

Transcription:

INSTITUTE FOR DEFENSE ANALYSES The Impact of Emerging Infectious Diseases on Military Operations 27 April 2016 Biological Medical Defense Conference Munich, GERMANY Julia K. Burr Robert L. Cubeta Jeffrey H. Grotte Lucas A. LaViolet Kate M. Sixt Monica Smith April 2016 Approved for public release; distribution is unlimited. IDA Paper NS P-5341 Log: H 16-000488 INSTITUTE FOR DEFENSE ANALYSES 4850 Mark Center Drive Alexandria, Virginia 22311-1882

The Institute for Defense Analyses is a non-profit corporation that operates three federally funded research and development centers to provide objective analyses of national security issues, particularly those requiring scientific and technical expertise, and conduct related research on other national challenges. About This Publication This work was conducted by the Institute for Defense Analyses under contract HQ0034-14-D-0001, Project CA-6-3774, Advanced Threats Study-Emerging Infectious Diseases, for the Joint Staff, Joint Requirements Office (JRO) for Chemical, Biological, Radiological and Nuclear (CBRN) Defense (J-8/JRO). The publication of this IDA document does not indicate endorsement by the Department of Defense, nor should the contents be construed as reflecting the official position of that Agency. Acknowledgments The authors wish to thank Dr. Nathan Platt and Mr. Jim Kurtz for their review. Copyright Notice 2016 Institute for Defense Analyses 4850 Mark Center Drive, Alexandria, Virginia 22311-1882 (703) 845-2000 This material may be reproduced by or for the U.S. Government pursuant to the copyright license under the clause at DFARS 252.227-7013 (a)(16) [June 2013].

INSTITUTE FOR DEFENSE ANALYSES IDA Paper NS P-5341 The Impact of Emerging Infectious Diseases on Military Operations 27 April 2016 Biological Medical Defense Conference Munich, GERMANY Julia K. Burr Robert L. Cubeta Jeffrey H. Grotte Lucas A. LaViolet Kate M. Sixt Monica Smith

This page is intentionally blank

The Impact of Emerging Infectious Diseases on Military Operations For the past 20 years, emerging infectious disease (EID) has been a growing concern of the national and international public health community. EIDs have the potential to decrease the effectiveness of military forces, both as a consequence of naturally occurring outbreaks within operating areas and when exploited by adversaries. The Institute for Defense Analyses (IDA) assessed the operational impact of EIDs on a military population in three scenarios: a naturally occurring disease outbreak; improvised use of EIDs as crude weapons or exploitation of an outbreak for operational gain; and the development and use of EIDs as biological weapons. These scenarios are represented very simply in the analysis presented here as 1, 10, and 100 initial infections. IDA developed a Susceptible, Exposed, Infected, and Removed (SEIR) Contagious Disease Model to predict the number of casualties resulting from four contagious diseases considered as surrogates for future EIDs of concern: smallpox, plague, the 1918 variant of influenza, and Severe Acute Respiratory Syndrome (SARS). The model uses a time-varying disease transmission rate based on data derived from historical outbreaks of these four diseases. It also incorporates a notional representation of military unit structure and personnel movement, in which the population at risk (PAR) is divided into semi-independent units. IDA used this model to evaluate two measures of operational impact: the time at which total casualties within the PAR exceeded 20% postulated here to be the point at which the PAR as a whole would become combat ineffective and the time at which a disease outbreak reached a specified unit. The time to combat ineffectiveness is an important determinant of the risk that EIDs pose to accomplishing operational objectives. An understanding of the time at which previously uninfected units become infected provides insight into the spread of the disease through the population structure, the requisite timeliness of implementing certain responses, and the information that might be provided through disease surveillance at the time a response must be implemented.

Contagious Disease Dynamics Model Probability of disease transmission (attack rate) Daily number of potential disease-causing close contacts per contagious individual Number and size of unit populations Number and location of initial infections Disease-specific parameters Movement rates between units Response parameters (immunization, prophylaxis, restriction of movement, isolation) Individual-Based Stochastic Susceptible, Exposed, Infected, Removed (SEIR) Model Run independently for each unit and number of initial infections Fully stochastic description of disease progression and transmission Random draws for: daily number of secondary infections per contagious individual, duration of latent and contagious periods, and fatalities Semi-Stochastic SEIR Model for Structured Populations Stochastic description of movement between units Deterministic description of disease progression and transmission (β) Random draws to select moving individuals from S, E, I, or R cohorts Time-varying disease transmission rate (β) Daily number of individuals in S, E, I, and R cohorts in each unit

Disease Parameters Parameter* SARS 1918 Influenza Smallpox Plague Incubation Period (days) Triangular distribution ( =8.5, =3.1) Lognormal distribution ( =1, =1) Normal distribution ( =15, =2.0) Normal distribution ( =3, =0.66) Contagious Period (days) Triangular distribution ( =9.3, =2.3) Lognormal distribution ( =5, =1) Normal distribution ( =11, =2.23) Normal distribution ( =3, =0.83) Case Fatality Rate 0.18 0.06 0.35 0.92 *Disease parameter value derived from historical outbreak data; documentation available upon request from the authors

Analytic Representation of Military Structure and Movement Unit 4 Unit 3 Unit 2a Unit 5 Unit 1 Analysis uses two force configurations: 10-unit force array with 27,800 personnel (Unit 2 considered as a single entity) Unit population average = 2,780 (Range 400-11,800) 4-unit force array with 2,800 personnel (Unit 2 divided into sub-units) Sub-unit population average = 700 (Range 400-1,300) Movement per unit ranged from 10-380 people/day Unit 7 Unit 8 Unit 6 Unit 2b Unit 2c Unit 2d Unit 2 = Default starting location of initial infections Unit 9 Unit 10 = Alternate starting location of initial infections

Time to 20% Casualties (Measure of Operational Impact #1) IDA estimated the time to combat ineffectiveness within the 10-unit force array for three diseases (influenza, plague, and smallpox) and 1, 10, and 100 initial infections. In all cases, casualties reached the postulated 20% threshold for combat ineffectiveness, assuming no interventions or alterations in population behavior. The length of time before casualties reached 20% varied substantially when compared across diseases and the number of initial infections. As expected, a greater number of initial infections resulted in the population becoming combat ineffective sooner. In the modeled outbreaks, diseases with shorter incubation periods consistently caused the population to become combat ineffective sooner than those with longer incubation periods: influenza outbreaks generated a 20% casualty rate within days, regardless of the number of initial infections, while smallpox outbreaks took weeks or months to do so. The modeling results presented here assume that the initial infections occurred in Unit 1, which is both the most populous unit and the one with the most direct connections to other units. To investigate the sensitivity of results relative to the location of initial infections and by extension the size of the unit and the number of connections to other units the IDA team conducted additional model runs in which initial infections occurred in Unit 7 and Unit 9. (Results shown here are for plague.) The team found that the time for outbreaks that started with fewer initial infections were less dependent on the location of the initial infections than those that started with a greater number of initial infections. In other words, the early behavior of outbreaks starting with fewer initial infections is dominated by the characteristics of the disease, while the early behavior of outbreaks starting with a greater number of initial infections is dominated by the structure and movement of the population.

Time to 20% Casualties in 10 Unit Force Array

Sensitivity of Time to 20% Casualties to Location of Initial Infections Time to 20% Casualties (Days), Plague, 10-Unit Force Array Number of Initial Infections Outbreak Start Location: Unit 1 Unit 7 Unit 9 1 300 328 312 10 119 111 156 100 61 48 130

Disease Spread Time (Time to Reach Unit n): Measure of Operational Impact #2 IDA used results from modeling SARS outbreaks in the smaller four-unit force array to assess the second measure of operational impact, disease spread time (defined as the time at which a disease outbreak reached a specified unit). The figure shown here illustrates the time it took the disease outbreak to spread from the unit where the initial infections were located to all other units for 1, 10, and 100 initial SARS infections. In the bar chart below, the length of the green bar shows the number of days during which the outbreak was contained within the unit in which it started. The length of the yellow bar represents the number of days during which the outbreak had spread beyond the first unit, but had not infected all four units. Finally, the point at which the red bar starts is the day the disease had spread to all units in the force array. In addition to revealing information about the timing of disease propagation across units, the figure also shows the number of symptomatic cases in the PAR by the aforementioned times. For example, in the one initial infection scenario, there were a total of two symptomatic individuals on day 24, when the infection first appeared outside of the first unit. For this measure, IDA evaluated the sensitivity of the results to both the patterns and rates at which individuals moved between units. The study team conducted additional SARS model runs using nine combinations of movement patterns and rates, as depicted in the figures below. As expected, all other factors being equal, the time it took for an outbreak to reach all units was inversely related to both movement rates and numbers of initial infections. The lower the movement rate and the smaller the number of initial infections, the longer the infection took to reach all units. The results were less sensitive to patterns of movement, although outbreaks spread somewhat faster when proportionately large numbers of individuals moved between the first unit and other units in the array.

Day of SARS Spread from Unit 1 to Unit n, 4-Unit Force Array

Sensitivity of Disease Spread Time to Movement Rates and Patterns: SARS, 4 Unit Force Array (1) Three Movement Patterns: Three Movement Rates: Balanced Unit 2a Skewed 2a-2b Unit 2a Skewed 2b-2d Unit 2a Low: ½ medium Medium: As shown in figure High: 2x medium 70 200 10 Unit 2b Unit 2b Unit 2b 70 70 30 10 30 200 Unit 2c 70 Unit 2d Unit 2c 40 Unit 2d Unit 2c 40 Unit 2d Numbers represent personnel who move between units each day

Sensitivity of Disease Spread Time to Movement Rates and Patterns: SARS, 4 Unit Force Array (2) Time at Which Outbreak Reaches All Units

Popout Section Text 1 The Challenge for Disease Surveillance While evaluating the second measure of effectiveness, the IDA team observed that when a disease spread from the first unit to another unit, there were typically few symptomatic cases of illness, and very often none. The fact that it is possible (and perhaps even likely) for the disease to spread from one unit to another prior to the onset of symptoms may have serious implications for a surveillance program that depends on identifying symptomatic individuals, as it may not be possible to prevent the disease spread in certain scenarios. In order to explore this concept, the IDA team performed a simple excursion to identify the scenarios in which an outbreak would be likely to spread before any individuals showed symptoms. The basic question the IDA team asked in this excursion was, In what circumstances is there a >50% probability that an exposed individual will move from the first unit to another unit before the first symptomatic case appears? Key variables are: Number of initial infections Movement rate Assumed time of first symptomatic case

Popout Section Figure

Popout Section Text 2 Each curve in the figure corresponds to the circumstances in which there is a 50% probability that the disease has spread beyond the first unit before the first symptomatic case. Above the curve are the circumstances in which the probability is greater than 50%, meaning there will likely be no symptomatic individuals to trigger intervention. Below the curve, however, the probability is less than 50%; these are the circumstances in which intervention based on observing a symptomatic individual could be effective at preventing the spread of disease. As a result, if the acceptable level of risk is 50%, the space below the curve represents situations that allow for action based on observing symptomatic individuals. Modern military operations are highly mobile, with individuals typically moving at rates of 20-25% per day. This suggests that during normal operations, with normal rates of personnel movement, any outbreak of contagious disease will likely spread beyond the unit in which it starts before the first symptomatic case occurs. If the first observable indicator of an EID outbreak is the presence of disease symptoms in an individual, preventing the spread of disease outside the initial unit will be challenging, if not impossible, in most cases.

Draft Layout Title and Narrative Contagious Disease Dynamics Model Analytical Representation of Military Structure and Movement Disease Parameters Table MOE #1 Title and Text Time to 20% Cas Chart Sensitivity to Location Of Initial Infections Popout Text #1 MOE #2 Title and Text Popout Figure Day of SARS Spread Bar Chart Popout Text #2 Movement Patterns Figure Time to All Units Chart

This page is intentionally blank.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE 3. DATES COVERED (From To) XX-04-2016 Final 4. TITLE AND SUBTITLE 5a. CONTRACT NO. The Impact of Emerging Infectious Diseases on Military Operations HQ0034-14-D-0001 5b. GRANT NO. 5c. PROGRAM ELEMENT NO(S). 6. AUTHOR(S) 5d. PROJECT NO. Julia K. Burr Robert L. Cubeta Jeffrey H. Grotte Lucas A. LaViolet Kate M. Sixt Monica Smith 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Institute for Defense Analyses Strategy, Forces and Resources Division 4850 Mark Center Drive Alexandria, VA 22311-1882 5e. TASK NO. CA-6-3774 5f. WORK UNIT NO. 8. PERFORMING ORGANIZATION REPORT NO. IDA Paper NS P-5341 Log: H 16-000488 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR S / MONITOR S ACRONYM(S) Joint Staff, J8, Joint Requirements Office for CBRN J-8/JRO-CBRN Defense Concepts, Studies, and Analyses Branch 8000 Joint Staff Pentagon, Room 1D958 Washington, DC 20318 11. SPONSOR S / MONITOR S REPORT NO(S). 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution is unlimited. 13. SUPPLEMENTARY NOTES Poster presentation to 2016 Bundeswehr Biological Medical Defense Conference, 27-29 April 2016, Munich GERMANY 14. ABSTRACT N/A 15. SUBJECT TERMS N/A 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NO. OF PAGES 19a. NAME OF RESPONSIBLE PERSON Mr. Jeffrey A. Steel a. REPORT b. ABSTRACT c. THIS PAGE U 24 19b. TELEPHONE NUMBER (Include Area Code) 703-571-3076 U U U Standard Form 298 (Rev. 8/98) Prescribed by ANSI Std. Z39.18

This page is intentionally blank.